And now,
kidneyintelX.dkd: what it is vs. what it’s not
| IS | IS NOT | |
|---|---|---|
| Focused, almost exclusively, on assisting nephrologists with their chronic kidney disease patients in stages 4 and 5 who are transitioning to dialysis or transplant. | ||
| Recognized as the first and only FDA authorized prognostic test for assessment of risk of chronic kidney disease progression. It sets the bar as a predicate for same or like medical tests to be reviewed by the FDA in the future. | ||
| Provides primary care doctors with a test to assess risk of progressive decline in kidney function in adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. This allows PCPs to identify risk earlier to improve kidney outcomes and overall patient health. | ||
| Our test reliably assesses where each adult patient with type 2 diabetes and with chronic kidney disease stages 1-3b falls on the risk spectrum for kidney disease progression (High/Moderate/Low). | ||
| Only test that leverages the three proprietary biomarkers demonstrated to be highly prognostic for chronic kidney disease progression. | ||
| Supported by a clinical validation study, kidneyintelX.dkd demonstrated an unadjusted HR for high vs low risk at 18-fold and 8-fold, respectively, when adjusted for age, sex, race, eGFR, UACR, A1C and BP. | ||
| The only test for progressive decline in kidney function with a national payment rate and final coverage determination from Medicare. |
Is:
Recognized as the first and only FDA authorized prognostic test for assessment of risk of chronic kidney disease progression. It sets the bar as a predicate for same or like medical tests to be reviewed by the FDA in the future.
Provides primary care doctors with a test to assess risk of progressive decline in kidney function in adult patients with type 2 diabetes and chronic kidney disease stages 1-3. This allows PCPs to identify risk earlier to improve kidney outcomes and overall patient health.
Our test reliably assesses where each adult patient with type 2 diabetes and with chronic kidney disease stages 1-3 falls on the risk spectrum for kidney disease progression (High/Moderate/Low).
Only test that leverages the three proprietary biomarkers demonstrated to be highly prognostic for chronic kidney disease progression.
Supported by a clinical validation study, kidneyintelX.dkd demonstrated an unadjusted HR for high vs low risk at 18-fold and 8-fold, respectively, when adjusted for age, sex, race, eGFR, UACR, A1C and BP.
The only test for progressive decline in kidney function with a national payment rate and final coverage determination from Medicare.
Is not:
Focused, almost exclusively, on assisting nephrologists with their chronic kidney disease patients in stages 4 and 5 who are transitioning to dialysis or transplant.